Jonathan B. Overdevest

Dec 19, 2024 | mdpi.com | Jonathan B. Overdevest

2. Materials and MethodsA total of 145 interested individuals were screened for enrollment. After applying inclusion criteria, 97 participants were enrolled in the study for baseline neuropsychiatric symptom reporting and olfactory psychophysical assessment, with 48 participants following up at one year. Individuals were recruited and evaluated in accordance with the proposed protocols (AAAU5380) approved by the Columbia University Irving Medical Center Institutional Review Board.

Jun 22, 2024 | onlinelibrary.wiley.com | Christine Liu |Jonathan B. Overdevest |Anna C. Zemke |Jess C. Mace

No abstract is available for this article. BIBLIOGRAPHY 1, , , et al. Predictors of sinonasal improvement after highly effective modulator therapy in adults with cystic fibrosis. Laryngoscope. 2024. https://doi.org/10.1002/lary.31438. 2, , , et al. Elexacaftor-tezacaftor-ivacaftor improves sinonasal outcomes in cystic fibrosis. J Cyst Fibros. 2022; 21(5): 792-799. https://doi.org/10.1016/j.jcf.2022.03.002. 3, , , et al.

Apr 18, 2024 | onlinelibrary.wiley.com | Daniel Beswick |Christine Liu |Jonathan B. Overdevest |Anna C. Zemke

INTRODUCTION Chronic rhinosinusitis (CRS) is prevalent in people with cystic fibrosis (PwCF).1-3 CRS in PwCF is associated with diminished quality of life (QOL), olfactory dysfunction, worse lower airway health, and increased treatment burden.4-6 Management approaches for CF-CRS are shifting with the introduction of highly effective CF transmembrane conductance regulator (CFTR) modulator therapy (HEMT), such as elexacaftor/tezacaftor/ivacaftor (ETI), which cause marked improvement in a wide...